Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Information
- Show
- FrequencyUpdated Biweekly
- PublishedJuly 14, 2025 at 2:32 PM UTC
- Length44 min
- RatingClean
